OperaV1, Main, Exploration, bibRecord, 001F48

Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects

Identifieur interne : 001F48 ( Main/Exploration ); précédent : 001F47; suivant : 001F49

Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects

Auteurs : S. Pöykkö [Finlande] ; O. Ukkola [Finlande] ; H. Kauma [Finlande] ; M. J. Savolainen [Finlande] ; Y. A. Kes Niemi [Finlande]

Source :

Diabetologia : (Berlin) [ 0012-186X ] ; 2003.

RBID : Pascal:03-0466710

English descriptors

KwdEn :
- Amino Acid Substitution (genetics), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (epidemiology), Diabetes Mellitus, Type 2 (genetics), Diabetic Angiopathies (epidemiology), Diabetic Angiopathies (genetics), Female, Ghrelin, Glucose Tolerance Test, Humans, Insulin-Like Growth Factor I (chemistry), Insulin-Like Growth Factor I (genetics), Male, Middle Aged, Mutation, Peptide Hormones (genetics), Random Allocation, Risk Factors.
MESH :
- chemical , chemistry : Insulin-Like Growth Factor I.
- chemical , genetics : Insulin-Like Growth Factor I, Peptide Hormones.
- chemical : Ghrelin.
- complications : Diabetes Mellitus, Type 2.
- epidemiology : Diabetes Mellitus, Type 2, Diabetic Angiopathies.
- genetics : Amino Acid Substitution, Diabetes Mellitus, Type 2, Diabetic Angiopathies.
- Female, Glucose Tolerance Test, Humans, Male, Middle Aged, Mutation, Random Allocation, Risk Factors.

Abstract

Aims/hypothesis. Experimental studies have suggested that ghrelin, a novel gastrointestinal peptide hormone, could play a role in glucose homeostasis. In addition, ghrelin has been associated with beneficial haemodynamic effects in experimental settings. Since the Arg51Gln mutation changes the carboxyterminal amino acid of the mature hormone and is associated with low ghrelin concentrations, we assessed the hypothesis that Arg51Gln mutation is a risk factor for Type 2 diabetes, impaired glucose tolerance, and hypertension. Methods. Blood pressure recordings and oral glucose tolerance test were carried out in the hypertensive (n=519) and control cohorts (n=526) of our well-defined OPERA study. The genotypes and plasma IGF-I and IGFBP- concentrations of 1031 subjects were analysed. Results. The ghrelin 51Gln allele was a risk factor for Type 2 diabetes, and the effect remained significant after adjustment for age, BMI, and study group (OR=2.53, CI: 1.11-5.75, p=0.027). In addition, the 51Gln allele was a risk factor for hypertension (OR=2.63, CI: 1.37-5.08, p=0.003). 51Gln carriers had lower concentrations of IGF-I and higher concentrations of IGFBP-1 compared to non-carriers. Conclusion/interpretation. The ghrelin 51Gln allele could increase the risk for Type 2 diabetes and hypertension. The low IGF-I concentrations in 51Gln carriers suggest that the mechanism might be associated with low GH concentrations.

Affiliations:

Finlande

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects</title>
<author><name sortKey="Poykko, S" sort="Poykko, S" uniqKey="Poykko S" first="S." last="Pöykkö">S. Pöykkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kauma, H" sort="Kauma, H" uniqKey="Kauma H" first="H." last="Kauma">H. Kauma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savolainen, M J" sort="Savolainen, M J" uniqKey="Savolainen M" first="M. J." last="Savolainen">M. J. Savolainen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0466710</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0466710 INIST</idno>
<idno type="RBID">Pascal:03-0466710</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000505</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000143</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000471</idno>
<idno type="wicri:doubleKey">0012-186X:2003:Poykko S:ghrelin:arg:gln</idno>
<idno type="wicri:Area/Main/Merge">002020</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12739020</idno>
<idno type="wicri:Area/PubMed/Corpus">000591</idno>
<idno type="wicri:Area/PubMed/Curation">000591</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000551</idno>
<idno type="wicri:Area/Ncbi/Merge">000153</idno>
<idno type="wicri:Area/Ncbi/Curation">000153</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000153</idno>
<idno type="wicri:doubleKey">0012-186X:2003:Poykko S:ghrelin:arg:gln</idno>
<idno type="wicri:Area/Main/Merge">001E81</idno>
<idno type="wicri:Area/Main/Curation">001F48</idno>
<idno type="wicri:Area/Main/Exploration">001F48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects</title>
<author><name sortKey="Poykko, S" sort="Poykko, S" uniqKey="Poykko S" first="S." last="Pöykkö">S. Pöykkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kauma, H" sort="Kauma, H" uniqKey="Kauma H" first="H." last="Kauma">H. Kauma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savolainen, M J" sort="Savolainen, M J" uniqKey="Savolainen M" first="M. J." last="Savolainen">M. J. Savolainen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<wicri:noRegion>Department of Internal Medicine and Biocenter Oulu, University of Oulu</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Substitution (genetics)</term>
<term>Diabetes Mellitus, Type 2 (complications)</term>
<term>Diabetes Mellitus, Type 2 (epidemiology)</term>
<term>Diabetes Mellitus, Type 2 (genetics)</term>
<term>Diabetic Angiopathies (epidemiology)</term>
<term>Diabetic Angiopathies (genetics)</term>
<term>Female</term>
<term>Ghrelin</term>
<term>Glucose Tolerance Test</term>
<term>Humans</term>
<term>Insulin-Like Growth Factor I (chemistry)</term>
<term>Insulin-Like Growth Factor I (genetics)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Peptide Hormones (genetics)</term>
<term>Random Allocation</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Insulin-Like Growth Factor I</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Insulin-Like Growth Factor I</term>
<term>Peptide Hormones</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Ghrelin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Diabetic Angiopathies</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Amino Acid Substitution</term>
<term>Diabetes Mellitus, Type 2</term>
<term>Diabetic Angiopathies</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Glucose Tolerance Test</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Random Allocation</term>
<term>Risk Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aims/hypothesis. Experimental studies have suggested that ghrelin, a novel gastrointestinal peptide hormone, could play a role in glucose homeostasis. In addition, ghrelin has been associated with beneficial haemodynamic effects in experimental settings. Since the Arg51Gln mutation changes the carboxyterminal amino acid of the mature hormone and is associated with low ghrelin concentrations, we assessed the hypothesis that Arg51Gln mutation is a risk factor for Type 2 diabetes, impaired glucose tolerance, and hypertension. Methods. Blood pressure recordings and oral glucose tolerance test were carried out in the hypertensive (n=519) and control cohorts (n=526) of our well-defined OPERA study. The genotypes and plasma IGF-I and IGFBP- concentrations of 1031 subjects were analysed. Results. The ghrelin 51Gln allele was a risk factor for Type 2 diabetes, and the effect remained significant after adjustment for age, BMI, and study group (OR=2.53, CI: 1.11-5.75, p=0.027). In addition, the 51Gln allele was a risk factor for hypertension (OR=2.63, CI: 1.37-5.08, p=0.003). 51Gln carriers had lower concentrations of IGF-I and higher concentrations of IGFBP-1 compared to non-carriers. Conclusion/interpretation. The ghrelin 51Gln allele could increase the risk for Type 2 diabetes and hypertension. The low IGF-I concentrations in 51Gln carriers suggest that the mechanism might be associated with low GH concentrations.</div>
</front>
</TEI>
<affiliations><list><country><li>Finlande</li>
</country>
</list>
<tree><country name="Finlande"><noRegion><name sortKey="Poykko, S" sort="Poykko, S" uniqKey="Poykko S" first="S." last="Pöykkö">S. Pöykkö</name>
</noRegion>
<name sortKey="Kauma, H" sort="Kauma, H" uniqKey="Kauma H" first="H." last="Kauma">H. Kauma</name>
<name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<name sortKey="Savolainen, M J" sort="Savolainen, M J" uniqKey="Savolainen M" first="M. J." last="Savolainen">M. J. Savolainen</name>
<name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F48 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F48 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:03-0466710
   |texte=   Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024

Serveur d'exploration sur l'opéra

Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects

Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.